Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkermes/Reliant Merger: Can Lescol Follow Altace Model?

Executive Summary

Alkermes hopes Lescol will follow the model of King's Altace as a late bloomer in the cardiovascular market following the proposed acquisition of Reliant Pharmaceuticals

You may also be interested in...



Lescol sNDA For Post-Angioplasty Adds 1 Mil. Potential Patients Per Year

Reliant will target the 1 mil. U.S. patients who undergo angioplasty procedures each year who could benefit from Lescol (fluvastatin) and Lescol XL after approval of an expanded indication for the statin May 27

Lescol sNDA For Post-Angioplasty Adds 1 Mil. Potential Patients Per Year

Reliant will target the 1 mil. U.S. patients who undergo angioplasty procedures each year who could benefit from Lescol (fluvastatin) and Lescol XL after approval of an expanded indication for the statin May 27

King Acquisition Strategy Will Be Driven By Late-Stage Product Deals

King Pharmaceuticals is shifting its acquisition strategy to either purchasing or in-licensing late-stage drugs rather than already-marketed products, the company told investors during a quarterly conference call May 6

Related Content

UsernamePublicRestriction

Register

PS039644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel